Global Selective Cox-2 Inhibitors Market Growth (Status and Outlook) 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “Selective Cox-2 Inhibitors Industry Forecast” looks at past sales and reviews total world Selective Cox-2 Inhibitors sales in 2022, providing a comprehensive analysis by region and market sector of projected Selective Cox-2 Inhibitors sales for 2023 through 2029. With Selective Cox-2 Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Selective Cox-2 Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Selective Cox-2 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Selective Cox-2 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Selective Cox-2 Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Selective Cox-2 Inhibitors and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Selective Cox-2 Inhibitors.
The global Selective Cox-2 Inhibitors market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Selective Cox-2 Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Selective Cox-2 Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Selective Cox-2 Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Selective Cox-2 Inhibitors players cover Boehringer-Ingelheim, TerSera Therapeutics, Iroko Pharmaceuticals, Apotex, Yung Shin Pharmaceutical, Breckenridge Pharmaceutical, Meda Pharmaceuticals, Cipla and Glenmark Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Selective Cox-2 Inhibitors market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
LPI (LP Information)' newest research report, the “Selective Cox-2 Inhibitors Industry Forecast” looks at past sales and reviews total world Selective Cox-2 Inhibitors sales in 2022, providing a comprehensive analysis by region and market sector of projected Selective Cox-2 Inhibitors sales for 2023 through 2029. With Selective Cox-2 Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Selective Cox-2 Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Selective Cox-2 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Selective Cox-2 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Selective Cox-2 Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Selective Cox-2 Inhibitors and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Selective Cox-2 Inhibitors.
The global Selective Cox-2 Inhibitors market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Selective Cox-2 Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Selective Cox-2 Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Selective Cox-2 Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Selective Cox-2 Inhibitors players cover Boehringer-Ingelheim, TerSera Therapeutics, Iroko Pharmaceuticals, Apotex, Yung Shin Pharmaceutical, Breckenridge Pharmaceutical, Meda Pharmaceuticals, Cipla and Glenmark Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Selective Cox-2 Inhibitors market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
- Meloxicam
- Celecoxib
- Etoricoxib
- Imrecoxib
- Etodolac
- Parecoxib
- Other
- Rheumatoid Arthritis
- Osteoarthritis
- Spondylosis Chronica Ankylopoietica
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Boehringer-Ingelheim
- TerSera Therapeutics
- Iroko Pharmaceuticals
- Apotex
- Yung Shin Pharmaceutical
- Breckenridge Pharmaceutical
- Meda Pharmaceuticals
- Cipla
- Glenmark Pharmaceuticals
- Teva
- PuraCap Pharmaceutical
- Almirall Limited
- Lupin Pharmaceuticals
- Aurobindo Pharma
- Pfizer
- Mylan
- Takeda
- Bayer
- Novacap
- Abbott
- Geri-Care
- Perrigo
- Kopran
- Merck
- Hengrui pharmaceutical
- Kelun Group
- Qilu Pharmaceutical
- Taro Pharmaceuticals
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Selective Cox-2 Inhibitors Market Size 2018-2029
2.1.2 Selective Cox-2 Inhibitors Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Selective Cox-2 Inhibitors Segment by Type
2.2.1 Meloxicam
2.2.2 Celecoxib
2.2.3 Etoricoxib
2.2.4 Imrecoxib
2.2.5 Etodolac
2.2.6 Parecoxib
2.2.7 Other
2.3 Selective Cox-2 Inhibitors Market Size by Type
2.3.1 Selective Cox-2 Inhibitors Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
2.4 Selective Cox-2 Inhibitors Segment by Application
2.4.1 Rheumatoid Arthritis
2.4.2 Osteoarthritis
2.4.3 Spondylosis Chronica Ankylopoietica
2.4.4 Other
2.5 Selective Cox-2 Inhibitors Market Size by Application
2.5.1 Selective Cox-2 Inhibitors Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
3 SELECTIVE COX-2 INHIBITORS MARKET SIZE BY PLAYER
3.1 Selective Cox-2 Inhibitors Market Size Market Share by Players
3.1.1 Global Selective Cox-2 Inhibitors Revenue by Players (2018-2023)
3.1.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Players (2018-2023)
3.2 Global Selective Cox-2 Inhibitors Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 SELECTIVE COX-2 INHIBITORS BY REGIONS
4.1 Selective Cox-2 Inhibitors Market Size by Regions (2018-2023)
4.2 Americas Selective Cox-2 Inhibitors Market Size Growth (2018-2023)
4.3 APAC Selective Cox-2 Inhibitors Market Size Growth (2018-2023)
4.4 Europe Selective Cox-2 Inhibitors Market Size Growth (2018-2023)
4.5 Middle East & Africa Selective Cox-2 Inhibitors Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Selective Cox-2 Inhibitors Market Size by Country (2018-2023)
5.2 Americas Selective Cox-2 Inhibitors Market Size by Type (2018-2023)
5.3 Americas Selective Cox-2 Inhibitors Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Selective Cox-2 Inhibitors Market Size by Region (2018-2023)
6.2 APAC Selective Cox-2 Inhibitors Market Size by Type (2018-2023)
6.3 APAC Selective Cox-2 Inhibitors Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Selective Cox-2 Inhibitors by Country (2018-2023)
7.2 Europe Selective Cox-2 Inhibitors Market Size by Type (2018-2023)
7.3 Europe Selective Cox-2 Inhibitors Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Selective Cox-2 Inhibitors by Region (2018-2023)
8.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2018-2023)
8.3 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL SELECTIVE COX-2 INHIBITORS MARKET FORECAST
10.1 Global Selective Cox-2 Inhibitors Forecast by Regions (2024-2029)
10.1.1 Global Selective Cox-2 Inhibitors Forecast by Regions (2024-2029)
10.1.2 Americas Selective Cox-2 Inhibitors Forecast
10.1.3 APAC Selective Cox-2 Inhibitors Forecast
10.1.4 Europe Selective Cox-2 Inhibitors Forecast
10.1.5 Middle East & Africa Selective Cox-2 Inhibitors Forecast
10.2 Americas Selective Cox-2 Inhibitors Forecast by Country (2024-2029)
10.2.1 United States Selective Cox-2 Inhibitors Market Forecast
10.2.2 Canada Selective Cox-2 Inhibitors Market Forecast
10.2.3 Mexico Selective Cox-2 Inhibitors Market Forecast
10.2.4 Brazil Selective Cox-2 Inhibitors Market Forecast
10.3 APAC Selective Cox-2 Inhibitors Forecast by Region (2024-2029)
10.3.1 China Selective Cox-2 Inhibitors Market Forecast
10.3.2 Japan Selective Cox-2 Inhibitors Market Forecast
10.3.3 Korea Selective Cox-2 Inhibitors Market Forecast
10.3.4 Southeast Asia Selective Cox-2 Inhibitors Market Forecast
10.3.5 India Selective Cox-2 Inhibitors Market Forecast
10.3.6 Australia Selective Cox-2 Inhibitors Market Forecast
10.4 Europe Selective Cox-2 Inhibitors Forecast by Country (2024-2029)
10.4.1 Germany Selective Cox-2 Inhibitors Market Forecast
10.4.2 France Selective Cox-2 Inhibitors Market Forecast
10.4.3 UK Selective Cox-2 Inhibitors Market Forecast
10.4.4 Italy Selective Cox-2 Inhibitors Market Forecast
10.4.5 Russia Selective Cox-2 Inhibitors Market Forecast
10.5 Middle East & Africa Selective Cox-2 Inhibitors Forecast by Region (2024-2029)
10.5.1 Egypt Selective Cox-2 Inhibitors Market Forecast
10.5.2 South Africa Selective Cox-2 Inhibitors Market Forecast
10.5.3 Israel Selective Cox-2 Inhibitors Market Forecast
10.5.4 Turkey Selective Cox-2 Inhibitors Market Forecast
10.5.5 GCC Countries Selective Cox-2 Inhibitors Market Forecast
10.6 Global Selective Cox-2 Inhibitors Forecast by Type (2024-2029)
10.7 Global Selective Cox-2 Inhibitors Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Boehringer-Ingelheim
11.1.1 Boehringer-Ingelheim Company Information
11.1.2 Boehringer-Ingelheim Selective Cox-2 Inhibitors Product Offered
11.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Boehringer-Ingelheim Main Business Overview
11.1.5 Boehringer-Ingelheim Latest Developments
11.2 TerSera Therapeutics
11.2.1 TerSera Therapeutics Company Information
11.2.2 TerSera Therapeutics Selective Cox-2 Inhibitors Product Offered
11.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 TerSera Therapeutics Main Business Overview
11.2.5 TerSera Therapeutics Latest Developments
11.3 Iroko Pharmaceuticals
11.3.1 Iroko Pharmaceuticals Company Information
11.3.2 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
11.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Iroko Pharmaceuticals Main Business Overview
11.3.5 Iroko Pharmaceuticals Latest Developments
11.4 Apotex
11.4.1 Apotex Company Information
11.4.2 Apotex Selective Cox-2 Inhibitors Product Offered
11.4.3 Apotex Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Apotex Main Business Overview
11.4.5 Apotex Latest Developments
11.5 Yung Shin Pharmaceutical
11.5.1 Yung Shin Pharmaceutical Company Information
11.5.2 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product Offered
11.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Yung Shin Pharmaceutical Main Business Overview
11.5.5 Yung Shin Pharmaceutical Latest Developments
11.6 Breckenridge Pharmaceutical
11.6.1 Breckenridge Pharmaceutical Company Information
11.6.2 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product Offered
11.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Breckenridge Pharmaceutical Main Business Overview
11.6.5 Breckenridge Pharmaceutical Latest Developments
11.7 Meda Pharmaceuticals
11.7.1 Meda Pharmaceuticals Company Information
11.7.2 Meda Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
11.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Meda Pharmaceuticals Main Business Overview
11.7.5 Meda Pharmaceuticals Latest Developments
11.8 Cipla
11.8.1 Cipla Company Information
11.8.2 Cipla Selective Cox-2 Inhibitors Product Offered
11.8.3 Cipla Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Cipla Main Business Overview
11.8.5 Cipla Latest Developments
11.9 Glenmark Pharmaceuticals
11.9.1 Glenmark Pharmaceuticals Company Information
11.9.2 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
11.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Glenmark Pharmaceuticals Main Business Overview
11.9.5 Glenmark Pharmaceuticals Latest Developments
11.10 Teva
11.10.1 Teva Company Information
11.10.2 Teva Selective Cox-2 Inhibitors Product Offered
11.10.3 Teva Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Teva Main Business Overview
11.10.5 Teva Latest Developments
11.11 PuraCap Pharmaceutical
11.11.1 PuraCap Pharmaceutical Company Information
11.11.2 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product Offered
11.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 PuraCap Pharmaceutical Main Business Overview
11.11.5 PuraCap Pharmaceutical Latest Developments
11.12 Almirall Limited
11.12.1 Almirall Limited Company Information
11.12.2 Almirall Limited Selective Cox-2 Inhibitors Product Offered
11.12.3 Almirall Limited Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Almirall Limited Main Business Overview
11.12.5 Almirall Limited Latest Developments
11.13 Lupin Pharmaceuticals
11.13.1 Lupin Pharmaceuticals Company Information
11.13.2 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
11.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Lupin Pharmaceuticals Main Business Overview
11.13.5 Lupin Pharmaceuticals Latest Developments
11.14 Aurobindo Pharma
11.14.1 Aurobindo Pharma Company Information
11.14.2 Aurobindo Pharma Selective Cox-2 Inhibitors Product Offered
11.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Aurobindo Pharma Main Business Overview
11.14.5 Aurobindo Pharma Latest Developments
11.15 Pfizer
11.15.1 Pfizer Company Information
11.15.2 Pfizer Selective Cox-2 Inhibitors Product Offered
11.15.3 Pfizer Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Pfizer Main Business Overview
11.15.5 Pfizer Latest Developments
11.16 Mylan
11.16.1 Mylan Company Information
11.16.2 Mylan Selective Cox-2 Inhibitors Product Offered
11.16.3 Mylan Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Mylan Main Business Overview
11.16.5 Mylan Latest Developments
11.17 Takeda
11.17.1 Takeda Company Information
11.17.2 Takeda Selective Cox-2 Inhibitors Product Offered
11.17.3 Takeda Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Takeda Main Business Overview
11.17.5 Takeda Latest Developments
11.18 Bayer
11.18.1 Bayer Company Information
11.18.2 Bayer Selective Cox-2 Inhibitors Product Offered
11.18.3 Bayer Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Bayer Main Business Overview
11.18.5 Bayer Latest Developments
11.19 Novacap
11.19.1 Novacap Company Information
11.19.2 Novacap Selective Cox-2 Inhibitors Product Offered
11.19.3 Novacap Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Novacap Main Business Overview
11.19.5 Novacap Latest Developments
11.20 Abbott
11.20.1 Abbott Company Information
11.20.2 Abbott Selective Cox-2 Inhibitors Product Offered
11.20.3 Abbott Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Abbott Main Business Overview
11.20.5 Abbott Latest Developments
11.21 Geri-Care
11.21.1 Geri-Care Company Information
11.21.2 Geri-Care Selective Cox-2 Inhibitors Product Offered
11.21.3 Geri-Care Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.21.4 Geri-Care Main Business Overview
11.21.5 Geri-Care Latest Developments
11.22 Perrigo
11.22.1 Perrigo Company Information
11.22.2 Perrigo Selective Cox-2 Inhibitors Product Offered
11.22.3 Perrigo Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.22.4 Perrigo Main Business Overview
11.22.5 Perrigo Latest Developments
11.23 Kopran
11.23.1 Kopran Company Information
11.23.2 Kopran Selective Cox-2 Inhibitors Product Offered
11.23.3 Kopran Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.23.4 Kopran Main Business Overview
11.23.5 Kopran Latest Developments
11.24 Merck
11.24.1 Merck Company Information
11.24.2 Merck Selective Cox-2 Inhibitors Product Offered
11.24.3 Merck Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.24.4 Merck Main Business Overview
11.24.5 Merck Latest Developments
11.25 Hengrui pharmaceutical
11.25.1 Hengrui pharmaceutical Company Information
11.25.2 Hengrui pharmaceutical Selective Cox-2 Inhibitors Product Offered
11.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.25.4 Hengrui pharmaceutical Main Business Overview
11.25.5 Hengrui pharmaceutical Latest Developments
11.26 Kelun Group
11.26.1 Kelun Group Company Information
11.26.2 Kelun Group Selective Cox-2 Inhibitors Product Offered
11.26.3 Kelun Group Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.26.4 Kelun Group Main Business Overview
11.26.5 Kelun Group Latest Developments
11.27 Qilu Pharmaceutical
11.27.1 Qilu Pharmaceutical Company Information
11.27.2 Qilu Pharmaceutical Selective Cox-2 Inhibitors Product Offered
11.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.27.4 Qilu Pharmaceutical Main Business Overview
11.27.5 Qilu Pharmaceutical Latest Developments
11.28 Taro Pharmaceuticals
11.28.1 Taro Pharmaceuticals Company Information
11.28.2 Taro Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
11.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.28.4 Taro Pharmaceuticals Main Business Overview
11.28.5 Taro Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Selective Cox-2 Inhibitors Market Size 2018-2029
2.1.2 Selective Cox-2 Inhibitors Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Selective Cox-2 Inhibitors Segment by Type
2.2.1 Meloxicam
2.2.2 Celecoxib
2.2.3 Etoricoxib
2.2.4 Imrecoxib
2.2.5 Etodolac
2.2.6 Parecoxib
2.2.7 Other
2.3 Selective Cox-2 Inhibitors Market Size by Type
2.3.1 Selective Cox-2 Inhibitors Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
2.4 Selective Cox-2 Inhibitors Segment by Application
2.4.1 Rheumatoid Arthritis
2.4.2 Osteoarthritis
2.4.3 Spondylosis Chronica Ankylopoietica
2.4.4 Other
2.5 Selective Cox-2 Inhibitors Market Size by Application
2.5.1 Selective Cox-2 Inhibitors Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
3 SELECTIVE COX-2 INHIBITORS MARKET SIZE BY PLAYER
3.1 Selective Cox-2 Inhibitors Market Size Market Share by Players
3.1.1 Global Selective Cox-2 Inhibitors Revenue by Players (2018-2023)
3.1.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Players (2018-2023)
3.2 Global Selective Cox-2 Inhibitors Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 SELECTIVE COX-2 INHIBITORS BY REGIONS
4.1 Selective Cox-2 Inhibitors Market Size by Regions (2018-2023)
4.2 Americas Selective Cox-2 Inhibitors Market Size Growth (2018-2023)
4.3 APAC Selective Cox-2 Inhibitors Market Size Growth (2018-2023)
4.4 Europe Selective Cox-2 Inhibitors Market Size Growth (2018-2023)
4.5 Middle East & Africa Selective Cox-2 Inhibitors Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Selective Cox-2 Inhibitors Market Size by Country (2018-2023)
5.2 Americas Selective Cox-2 Inhibitors Market Size by Type (2018-2023)
5.3 Americas Selective Cox-2 Inhibitors Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Selective Cox-2 Inhibitors Market Size by Region (2018-2023)
6.2 APAC Selective Cox-2 Inhibitors Market Size by Type (2018-2023)
6.3 APAC Selective Cox-2 Inhibitors Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Selective Cox-2 Inhibitors by Country (2018-2023)
7.2 Europe Selective Cox-2 Inhibitors Market Size by Type (2018-2023)
7.3 Europe Selective Cox-2 Inhibitors Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Selective Cox-2 Inhibitors by Region (2018-2023)
8.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2018-2023)
8.3 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL SELECTIVE COX-2 INHIBITORS MARKET FORECAST
10.1 Global Selective Cox-2 Inhibitors Forecast by Regions (2024-2029)
10.1.1 Global Selective Cox-2 Inhibitors Forecast by Regions (2024-2029)
10.1.2 Americas Selective Cox-2 Inhibitors Forecast
10.1.3 APAC Selective Cox-2 Inhibitors Forecast
10.1.4 Europe Selective Cox-2 Inhibitors Forecast
10.1.5 Middle East & Africa Selective Cox-2 Inhibitors Forecast
10.2 Americas Selective Cox-2 Inhibitors Forecast by Country (2024-2029)
10.2.1 United States Selective Cox-2 Inhibitors Market Forecast
10.2.2 Canada Selective Cox-2 Inhibitors Market Forecast
10.2.3 Mexico Selective Cox-2 Inhibitors Market Forecast
10.2.4 Brazil Selective Cox-2 Inhibitors Market Forecast
10.3 APAC Selective Cox-2 Inhibitors Forecast by Region (2024-2029)
10.3.1 China Selective Cox-2 Inhibitors Market Forecast
10.3.2 Japan Selective Cox-2 Inhibitors Market Forecast
10.3.3 Korea Selective Cox-2 Inhibitors Market Forecast
10.3.4 Southeast Asia Selective Cox-2 Inhibitors Market Forecast
10.3.5 India Selective Cox-2 Inhibitors Market Forecast
10.3.6 Australia Selective Cox-2 Inhibitors Market Forecast
10.4 Europe Selective Cox-2 Inhibitors Forecast by Country (2024-2029)
10.4.1 Germany Selective Cox-2 Inhibitors Market Forecast
10.4.2 France Selective Cox-2 Inhibitors Market Forecast
10.4.3 UK Selective Cox-2 Inhibitors Market Forecast
10.4.4 Italy Selective Cox-2 Inhibitors Market Forecast
10.4.5 Russia Selective Cox-2 Inhibitors Market Forecast
10.5 Middle East & Africa Selective Cox-2 Inhibitors Forecast by Region (2024-2029)
10.5.1 Egypt Selective Cox-2 Inhibitors Market Forecast
10.5.2 South Africa Selective Cox-2 Inhibitors Market Forecast
10.5.3 Israel Selective Cox-2 Inhibitors Market Forecast
10.5.4 Turkey Selective Cox-2 Inhibitors Market Forecast
10.5.5 GCC Countries Selective Cox-2 Inhibitors Market Forecast
10.6 Global Selective Cox-2 Inhibitors Forecast by Type (2024-2029)
10.7 Global Selective Cox-2 Inhibitors Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Boehringer-Ingelheim
11.1.1 Boehringer-Ingelheim Company Information
11.1.2 Boehringer-Ingelheim Selective Cox-2 Inhibitors Product Offered
11.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Boehringer-Ingelheim Main Business Overview
11.1.5 Boehringer-Ingelheim Latest Developments
11.2 TerSera Therapeutics
11.2.1 TerSera Therapeutics Company Information
11.2.2 TerSera Therapeutics Selective Cox-2 Inhibitors Product Offered
11.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 TerSera Therapeutics Main Business Overview
11.2.5 TerSera Therapeutics Latest Developments
11.3 Iroko Pharmaceuticals
11.3.1 Iroko Pharmaceuticals Company Information
11.3.2 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
11.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Iroko Pharmaceuticals Main Business Overview
11.3.5 Iroko Pharmaceuticals Latest Developments
11.4 Apotex
11.4.1 Apotex Company Information
11.4.2 Apotex Selective Cox-2 Inhibitors Product Offered
11.4.3 Apotex Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Apotex Main Business Overview
11.4.5 Apotex Latest Developments
11.5 Yung Shin Pharmaceutical
11.5.1 Yung Shin Pharmaceutical Company Information
11.5.2 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product Offered
11.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Yung Shin Pharmaceutical Main Business Overview
11.5.5 Yung Shin Pharmaceutical Latest Developments
11.6 Breckenridge Pharmaceutical
11.6.1 Breckenridge Pharmaceutical Company Information
11.6.2 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product Offered
11.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Breckenridge Pharmaceutical Main Business Overview
11.6.5 Breckenridge Pharmaceutical Latest Developments
11.7 Meda Pharmaceuticals
11.7.1 Meda Pharmaceuticals Company Information
11.7.2 Meda Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
11.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Meda Pharmaceuticals Main Business Overview
11.7.5 Meda Pharmaceuticals Latest Developments
11.8 Cipla
11.8.1 Cipla Company Information
11.8.2 Cipla Selective Cox-2 Inhibitors Product Offered
11.8.3 Cipla Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Cipla Main Business Overview
11.8.5 Cipla Latest Developments
11.9 Glenmark Pharmaceuticals
11.9.1 Glenmark Pharmaceuticals Company Information
11.9.2 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
11.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Glenmark Pharmaceuticals Main Business Overview
11.9.5 Glenmark Pharmaceuticals Latest Developments
11.10 Teva
11.10.1 Teva Company Information
11.10.2 Teva Selective Cox-2 Inhibitors Product Offered
11.10.3 Teva Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Teva Main Business Overview
11.10.5 Teva Latest Developments
11.11 PuraCap Pharmaceutical
11.11.1 PuraCap Pharmaceutical Company Information
11.11.2 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product Offered
11.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 PuraCap Pharmaceutical Main Business Overview
11.11.5 PuraCap Pharmaceutical Latest Developments
11.12 Almirall Limited
11.12.1 Almirall Limited Company Information
11.12.2 Almirall Limited Selective Cox-2 Inhibitors Product Offered
11.12.3 Almirall Limited Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Almirall Limited Main Business Overview
11.12.5 Almirall Limited Latest Developments
11.13 Lupin Pharmaceuticals
11.13.1 Lupin Pharmaceuticals Company Information
11.13.2 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
11.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Lupin Pharmaceuticals Main Business Overview
11.13.5 Lupin Pharmaceuticals Latest Developments
11.14 Aurobindo Pharma
11.14.1 Aurobindo Pharma Company Information
11.14.2 Aurobindo Pharma Selective Cox-2 Inhibitors Product Offered
11.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Aurobindo Pharma Main Business Overview
11.14.5 Aurobindo Pharma Latest Developments
11.15 Pfizer
11.15.1 Pfizer Company Information
11.15.2 Pfizer Selective Cox-2 Inhibitors Product Offered
11.15.3 Pfizer Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Pfizer Main Business Overview
11.15.5 Pfizer Latest Developments
11.16 Mylan
11.16.1 Mylan Company Information
11.16.2 Mylan Selective Cox-2 Inhibitors Product Offered
11.16.3 Mylan Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Mylan Main Business Overview
11.16.5 Mylan Latest Developments
11.17 Takeda
11.17.1 Takeda Company Information
11.17.2 Takeda Selective Cox-2 Inhibitors Product Offered
11.17.3 Takeda Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Takeda Main Business Overview
11.17.5 Takeda Latest Developments
11.18 Bayer
11.18.1 Bayer Company Information
11.18.2 Bayer Selective Cox-2 Inhibitors Product Offered
11.18.3 Bayer Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Bayer Main Business Overview
11.18.5 Bayer Latest Developments
11.19 Novacap
11.19.1 Novacap Company Information
11.19.2 Novacap Selective Cox-2 Inhibitors Product Offered
11.19.3 Novacap Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Novacap Main Business Overview
11.19.5 Novacap Latest Developments
11.20 Abbott
11.20.1 Abbott Company Information
11.20.2 Abbott Selective Cox-2 Inhibitors Product Offered
11.20.3 Abbott Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Abbott Main Business Overview
11.20.5 Abbott Latest Developments
11.21 Geri-Care
11.21.1 Geri-Care Company Information
11.21.2 Geri-Care Selective Cox-2 Inhibitors Product Offered
11.21.3 Geri-Care Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.21.4 Geri-Care Main Business Overview
11.21.5 Geri-Care Latest Developments
11.22 Perrigo
11.22.1 Perrigo Company Information
11.22.2 Perrigo Selective Cox-2 Inhibitors Product Offered
11.22.3 Perrigo Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.22.4 Perrigo Main Business Overview
11.22.5 Perrigo Latest Developments
11.23 Kopran
11.23.1 Kopran Company Information
11.23.2 Kopran Selective Cox-2 Inhibitors Product Offered
11.23.3 Kopran Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.23.4 Kopran Main Business Overview
11.23.5 Kopran Latest Developments
11.24 Merck
11.24.1 Merck Company Information
11.24.2 Merck Selective Cox-2 Inhibitors Product Offered
11.24.3 Merck Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.24.4 Merck Main Business Overview
11.24.5 Merck Latest Developments
11.25 Hengrui pharmaceutical
11.25.1 Hengrui pharmaceutical Company Information
11.25.2 Hengrui pharmaceutical Selective Cox-2 Inhibitors Product Offered
11.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.25.4 Hengrui pharmaceutical Main Business Overview
11.25.5 Hengrui pharmaceutical Latest Developments
11.26 Kelun Group
11.26.1 Kelun Group Company Information
11.26.2 Kelun Group Selective Cox-2 Inhibitors Product Offered
11.26.3 Kelun Group Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.26.4 Kelun Group Main Business Overview
11.26.5 Kelun Group Latest Developments
11.27 Qilu Pharmaceutical
11.27.1 Qilu Pharmaceutical Company Information
11.27.2 Qilu Pharmaceutical Selective Cox-2 Inhibitors Product Offered
11.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.27.4 Qilu Pharmaceutical Main Business Overview
11.27.5 Qilu Pharmaceutical Latest Developments
11.28 Taro Pharmaceuticals
11.28.1 Taro Pharmaceuticals Company Information
11.28.2 Taro Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
11.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
11.28.4 Taro Pharmaceuticals Main Business Overview
11.28.5 Taro Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Selective Cox-2 Inhibitors Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Meloxicam
Table 3. Major Players of Celecoxib
Table 4. Major Players of Etoricoxib
Table 5. Major Players of Imrecoxib
Table 6. Major Players of Etodolac
Table 7. Major Players of Parecoxib
Table 8. Major Players of Other
Table 9. Selective Cox-2 Inhibitors Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 10. Global Selective Cox-2 Inhibitors Market Size by Type (2018-2023) & ($ Millions)
Table 11. Global Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
Table 12. Selective Cox-2 Inhibitors Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 13. Global Selective Cox-2 Inhibitors Market Size by Application (2018-2023) & ($ Millions)
Table 14. Global Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
Table 15. Global Selective Cox-2 Inhibitors Revenue by Players (2018-2023) & ($ Millions)
Table 16. Global Selective Cox-2 Inhibitors Revenue Market Share by Player (2018-2023)
Table 17. Selective Cox-2 Inhibitors Key Players Head office and Products Offered
Table 18. Selective Cox-2 Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 19. New Products and Potential Entrants
Table 20. Mergers & Acquisitions, Expansion
Table 21. Global Selective Cox-2 Inhibitors Market Size by Regions 2018-2023 & ($ Millions)
Table 22. Global Selective Cox-2 Inhibitors Market Size Market Share by Regions (2018-2023)
Table 23. Global Selective Cox-2 Inhibitors Revenue by Country/Region (2018-2023) & ($ millions)
Table 24. Global Selective Cox-2 Inhibitors Revenue Market Share by Country/Region (2018-2023)
Table 25. Americas Selective Cox-2 Inhibitors Market Size by Country (2018-2023) & ($ Millions)
Table 26. Americas Selective Cox-2 Inhibitors Market Size Market Share by Country (2018-2023)
Table 27. Americas Selective Cox-2 Inhibitors Market Size by Type (2018-2023) & ($ Millions)
Table 28. Americas Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
Table 29. Americas Selective Cox-2 Inhibitors Market Size by Application (2018-2023) & ($ Millions)
Table 30. Americas Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
Table 31. APAC Selective Cox-2 Inhibitors Market Size by Region (2018-2023) & ($ Millions)
Table 32. APAC Selective Cox-2 Inhibitors Market Size Market Share by Region (2018-2023)
Table 33. APAC Selective Cox-2 Inhibitors Market Size by Type (2018-2023) & ($ Millions)
Table 34. APAC Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
Table 35. APAC Selective Cox-2 Inhibitors Market Size by Application (2018-2023) & ($ Millions)
Table 36. APAC Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
Table 37. Europe Selective Cox-2 Inhibitors Market Size by Country (2018-2023) & ($ Millions)
Table 38. Europe Selective Cox-2 Inhibitors Market Size Market Share by Country (2018-2023)
Table 39. Europe Selective Cox-2 Inhibitors Market Size by Type (2018-2023) & ($ Millions)
Table 40. Europe Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
Table 41. Europe Selective Cox-2 Inhibitors Market Size by Application (2018-2023) & ($ Millions)
Table 42. Europe Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
Table 43. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Region (2018-2023) & ($ Millions)
Table 44. Middle East & Africa Selective Cox-2 Inhibitors Market Size Market Share by Region (2018-2023)
Table 45. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2018-2023) & ($ Millions)
Table 46. Middle East & Africa Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
Table 47. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2018-2023) & ($ Millions)
Table 48. Middle East & Africa Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
Table 49. Key Market Drivers & Growth Opportunities of Selective Cox-2 Inhibitors
Table 50. Key Market Challenges & Risks of Selective Cox-2 Inhibitors
Table 51. Key Industry Trends of Selective Cox-2 Inhibitors
Table 52. Global Selective Cox-2 Inhibitors Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 53. Global Selective Cox-2 Inhibitors Market Size Market Share Forecast by Regions (2024-2029)
Table 54. Global Selective Cox-2 Inhibitors Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 55. Global Selective Cox-2 Inhibitors Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 56. Boehringer-Ingelheim Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 57. Boehringer-Ingelheim Selective Cox-2 Inhibitors Product Offered
Table 58. Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 59. Boehringer-Ingelheim Main Business
Table 60. Boehringer-Ingelheim Latest Developments
Table 61. TerSera Therapeutics Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 62. TerSera Therapeutics Selective Cox-2 Inhibitors Product Offered
Table 63. TerSera Therapeutics Main Business
Table 64. TerSera Therapeutics Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. TerSera Therapeutics Latest Developments
Table 66. Iroko Pharmaceuticals Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 67. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
Table 68. Iroko Pharmaceuticals Main Business
Table 69. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. Iroko Pharmaceuticals Latest Developments
Table 71. Apotex Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 72. Apotex Selective Cox-2 Inhibitors Product Offered
Table 73. Apotex Main Business
Table 74. Apotex Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. Apotex Latest Developments
Table 76. Yung Shin Pharmaceutical Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 77. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product Offered
Table 78. Yung Shin Pharmaceutical Main Business
Table 79. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. Yung Shin Pharmaceutical Latest Developments
Table 81. Breckenridge Pharmaceutical Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 82. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product Offered
Table 83. Breckenridge Pharmaceutical Main Business
Table 84. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 85. Breckenridge Pharmaceutical Latest Developments
Table 86. Meda Pharmaceuticals Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 87. Meda Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
Table 88. Meda Pharmaceuticals Main Business
Table 89. Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 90. Meda Pharmaceuticals Latest Developments
Table 91. Cipla Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 92. Cipla Selective Cox-2 Inhibitors Product Offered
Table 93. Cipla Main Business
Table 94. Cipla Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 95. Cipla Latest Developments
Table 96. Glenmark Pharmaceuticals Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 97. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
Table 98. Glenmark Pharmaceuticals Main Business
Table 99. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 100. Glenmark Pharmaceuticals Latest Developments
Table 101. Teva Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 102. Teva Selective Cox-2 Inhibitors Product Offered
Table 103. Teva Main Business
Table 104. Teva Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 105. Teva Latest Developments
Table 106. PuraCap Pharmaceutical Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 107. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product Offered
Table 108. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 109. PuraCap Pharmaceutical Main Business
Table 110. PuraCap Pharmaceutical Latest Developments
Table 111. Almirall Limited Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 112. Almirall Limited Selective Cox-2 Inhibitors Product Offered
Table 113. Almirall Limited Main Business
Table 114. Almirall Limited Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 115. Almirall Limited Latest Developments
Table 116. Lupin Pharmaceuticals Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 117. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
Table 118. Lupin Pharmaceuticals Main Business
Table 119. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 120. Lupin Pharmaceuticals Latest Developments
Table 121. Aurobindo Pharma Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 122. Aurobindo Pharma Selective Cox-2 Inhibitors Product Offered
Table 123. Aurobindo Pharma Main Business
Table 124. Aurobindo Pharma Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 125. Aurobindo Pharma Latest Developments
Table 126. Pfizer Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 127. Pfizer Selective Cox-2 Inhibitors Product Offered
Table 128. Pfizer Main Business
Table 129. Pfizer Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 130. Pfizer Latest Developments
Table 131. Mylan Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 132. Mylan Selective Cox-2 Inhibitors Product Offered
Table 133. Mylan Main Business
Table 134. Mylan Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 135. Mylan Latest Developments
Table 136. Takeda Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 137. Takeda Selective Cox-2 Inhibitors Product Offered
Table 138. Takeda Main Business
Table 139. Takeda Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 140. Takeda Latest Developments
Table 141. Bayer Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 142. Bayer Selective Cox-2 Inhibitors Product Offered
Table 143. Bayer Main Business
Table 144. Bayer Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 145. Bayer Latest Developments
Table 146. Novacap Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 147. Novacap Selective Cox-2 Inhibitors Product Offered
Table 148. Novacap Main Business
Table 149. Novacap Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 150. Novacap Latest Developments
Table 151. Abbott Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 152. Abbott Selective Cox-2 Inhibitors Product Offered
Table 153. Abbott Main Business
Table 154. Abbott Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 155. Abbott Latest Developments
Table 156. Geri-Care Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 157. Geri-Care Selective Cox-2 Inhibitors Product Offered
Table 158. Geri-Care Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 159. Geri-Care Main Business
Table 160. Geri-Care Latest Developments
Table 161. Perrigo Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 162. Perrigo Selective Cox-2 Inhibitors Product Offered
Table 163. Perrigo Main Business
Table 164. Perrigo Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 165. Perrigo Latest Developments
Table 166. Kopran Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 167. Kopran Selective Cox-2 Inhibitors Product Offered
Table 168. Kopran Main Business
Table 169. Kopran Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 170. Kopran Latest Developments
Table 171. Merck Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 172. Merck Selective Cox-2 Inhibitors Product Offered
Table 173. Merck Main Business
Table 174. Merck Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 175. Merck Latest Developments
Table 176. Hengrui pharmaceutical Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 177. Hengrui pharmaceutical Selective Cox-2 Inhibitors Product Offered
Table 178. Hengrui pharmaceutical Main Business
Table 179. Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 180. Hengrui pharmaceutical Latest Developments
Table 181. Kelun Group Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 182. Kelun Group Selective Cox-2 Inhibitors Product Offered
Table 183. Kelun Group Main Business
Table 184. Kelun Group Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 185. Kelun Group Latest Developments
Table 186. Qilu Pharmaceutical Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 187. Qilu Pharmaceutical Selective Cox-2 Inhibitors Product Offered
Table 188. Qilu Pharmaceutical Main Business
Table 189. Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 190. Qilu Pharmaceutical Latest Developments
Table 191. Taro Pharmaceuticals Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 192. Taro Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
Table 193. Taro Pharmaceuticals Main Business
Table 194. Taro Pharmaceuticals Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 195. Taro Pharmaceuticals Latest Developments
Table 1. Selective Cox-2 Inhibitors Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Meloxicam
Table 3. Major Players of Celecoxib
Table 4. Major Players of Etoricoxib
Table 5. Major Players of Imrecoxib
Table 6. Major Players of Etodolac
Table 7. Major Players of Parecoxib
Table 8. Major Players of Other
Table 9. Selective Cox-2 Inhibitors Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 10. Global Selective Cox-2 Inhibitors Market Size by Type (2018-2023) & ($ Millions)
Table 11. Global Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
Table 12. Selective Cox-2 Inhibitors Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 13. Global Selective Cox-2 Inhibitors Market Size by Application (2018-2023) & ($ Millions)
Table 14. Global Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
Table 15. Global Selective Cox-2 Inhibitors Revenue by Players (2018-2023) & ($ Millions)
Table 16. Global Selective Cox-2 Inhibitors Revenue Market Share by Player (2018-2023)
Table 17. Selective Cox-2 Inhibitors Key Players Head office and Products Offered
Table 18. Selective Cox-2 Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 19. New Products and Potential Entrants
Table 20. Mergers & Acquisitions, Expansion
Table 21. Global Selective Cox-2 Inhibitors Market Size by Regions 2018-2023 & ($ Millions)
Table 22. Global Selective Cox-2 Inhibitors Market Size Market Share by Regions (2018-2023)
Table 23. Global Selective Cox-2 Inhibitors Revenue by Country/Region (2018-2023) & ($ millions)
Table 24. Global Selective Cox-2 Inhibitors Revenue Market Share by Country/Region (2018-2023)
Table 25. Americas Selective Cox-2 Inhibitors Market Size by Country (2018-2023) & ($ Millions)
Table 26. Americas Selective Cox-2 Inhibitors Market Size Market Share by Country (2018-2023)
Table 27. Americas Selective Cox-2 Inhibitors Market Size by Type (2018-2023) & ($ Millions)
Table 28. Americas Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
Table 29. Americas Selective Cox-2 Inhibitors Market Size by Application (2018-2023) & ($ Millions)
Table 30. Americas Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
Table 31. APAC Selective Cox-2 Inhibitors Market Size by Region (2018-2023) & ($ Millions)
Table 32. APAC Selective Cox-2 Inhibitors Market Size Market Share by Region (2018-2023)
Table 33. APAC Selective Cox-2 Inhibitors Market Size by Type (2018-2023) & ($ Millions)
Table 34. APAC Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
Table 35. APAC Selective Cox-2 Inhibitors Market Size by Application (2018-2023) & ($ Millions)
Table 36. APAC Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
Table 37. Europe Selective Cox-2 Inhibitors Market Size by Country (2018-2023) & ($ Millions)
Table 38. Europe Selective Cox-2 Inhibitors Market Size Market Share by Country (2018-2023)
Table 39. Europe Selective Cox-2 Inhibitors Market Size by Type (2018-2023) & ($ Millions)
Table 40. Europe Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
Table 41. Europe Selective Cox-2 Inhibitors Market Size by Application (2018-2023) & ($ Millions)
Table 42. Europe Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
Table 43. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Region (2018-2023) & ($ Millions)
Table 44. Middle East & Africa Selective Cox-2 Inhibitors Market Size Market Share by Region (2018-2023)
Table 45. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2018-2023) & ($ Millions)
Table 46. Middle East & Africa Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
Table 47. Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2018-2023) & ($ Millions)
Table 48. Middle East & Africa Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
Table 49. Key Market Drivers & Growth Opportunities of Selective Cox-2 Inhibitors
Table 50. Key Market Challenges & Risks of Selective Cox-2 Inhibitors
Table 51. Key Industry Trends of Selective Cox-2 Inhibitors
Table 52. Global Selective Cox-2 Inhibitors Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 53. Global Selective Cox-2 Inhibitors Market Size Market Share Forecast by Regions (2024-2029)
Table 54. Global Selective Cox-2 Inhibitors Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 55. Global Selective Cox-2 Inhibitors Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 56. Boehringer-Ingelheim Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 57. Boehringer-Ingelheim Selective Cox-2 Inhibitors Product Offered
Table 58. Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 59. Boehringer-Ingelheim Main Business
Table 60. Boehringer-Ingelheim Latest Developments
Table 61. TerSera Therapeutics Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 62. TerSera Therapeutics Selective Cox-2 Inhibitors Product Offered
Table 63. TerSera Therapeutics Main Business
Table 64. TerSera Therapeutics Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. TerSera Therapeutics Latest Developments
Table 66. Iroko Pharmaceuticals Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 67. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
Table 68. Iroko Pharmaceuticals Main Business
Table 69. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. Iroko Pharmaceuticals Latest Developments
Table 71. Apotex Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 72. Apotex Selective Cox-2 Inhibitors Product Offered
Table 73. Apotex Main Business
Table 74. Apotex Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. Apotex Latest Developments
Table 76. Yung Shin Pharmaceutical Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 77. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product Offered
Table 78. Yung Shin Pharmaceutical Main Business
Table 79. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. Yung Shin Pharmaceutical Latest Developments
Table 81. Breckenridge Pharmaceutical Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 82. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product Offered
Table 83. Breckenridge Pharmaceutical Main Business
Table 84. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 85. Breckenridge Pharmaceutical Latest Developments
Table 86. Meda Pharmaceuticals Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 87. Meda Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
Table 88. Meda Pharmaceuticals Main Business
Table 89. Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 90. Meda Pharmaceuticals Latest Developments
Table 91. Cipla Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 92. Cipla Selective Cox-2 Inhibitors Product Offered
Table 93. Cipla Main Business
Table 94. Cipla Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 95. Cipla Latest Developments
Table 96. Glenmark Pharmaceuticals Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 97. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
Table 98. Glenmark Pharmaceuticals Main Business
Table 99. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 100. Glenmark Pharmaceuticals Latest Developments
Table 101. Teva Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 102. Teva Selective Cox-2 Inhibitors Product Offered
Table 103. Teva Main Business
Table 104. Teva Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 105. Teva Latest Developments
Table 106. PuraCap Pharmaceutical Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 107. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product Offered
Table 108. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 109. PuraCap Pharmaceutical Main Business
Table 110. PuraCap Pharmaceutical Latest Developments
Table 111. Almirall Limited Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 112. Almirall Limited Selective Cox-2 Inhibitors Product Offered
Table 113. Almirall Limited Main Business
Table 114. Almirall Limited Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 115. Almirall Limited Latest Developments
Table 116. Lupin Pharmaceuticals Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 117. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
Table 118. Lupin Pharmaceuticals Main Business
Table 119. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 120. Lupin Pharmaceuticals Latest Developments
Table 121. Aurobindo Pharma Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 122. Aurobindo Pharma Selective Cox-2 Inhibitors Product Offered
Table 123. Aurobindo Pharma Main Business
Table 124. Aurobindo Pharma Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 125. Aurobindo Pharma Latest Developments
Table 126. Pfizer Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 127. Pfizer Selective Cox-2 Inhibitors Product Offered
Table 128. Pfizer Main Business
Table 129. Pfizer Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 130. Pfizer Latest Developments
Table 131. Mylan Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 132. Mylan Selective Cox-2 Inhibitors Product Offered
Table 133. Mylan Main Business
Table 134. Mylan Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 135. Mylan Latest Developments
Table 136. Takeda Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 137. Takeda Selective Cox-2 Inhibitors Product Offered
Table 138. Takeda Main Business
Table 139. Takeda Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 140. Takeda Latest Developments
Table 141. Bayer Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 142. Bayer Selective Cox-2 Inhibitors Product Offered
Table 143. Bayer Main Business
Table 144. Bayer Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 145. Bayer Latest Developments
Table 146. Novacap Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 147. Novacap Selective Cox-2 Inhibitors Product Offered
Table 148. Novacap Main Business
Table 149. Novacap Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 150. Novacap Latest Developments
Table 151. Abbott Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 152. Abbott Selective Cox-2 Inhibitors Product Offered
Table 153. Abbott Main Business
Table 154. Abbott Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 155. Abbott Latest Developments
Table 156. Geri-Care Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 157. Geri-Care Selective Cox-2 Inhibitors Product Offered
Table 158. Geri-Care Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 159. Geri-Care Main Business
Table 160. Geri-Care Latest Developments
Table 161. Perrigo Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 162. Perrigo Selective Cox-2 Inhibitors Product Offered
Table 163. Perrigo Main Business
Table 164. Perrigo Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 165. Perrigo Latest Developments
Table 166. Kopran Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 167. Kopran Selective Cox-2 Inhibitors Product Offered
Table 168. Kopran Main Business
Table 169. Kopran Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 170. Kopran Latest Developments
Table 171. Merck Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 172. Merck Selective Cox-2 Inhibitors Product Offered
Table 173. Merck Main Business
Table 174. Merck Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 175. Merck Latest Developments
Table 176. Hengrui pharmaceutical Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 177. Hengrui pharmaceutical Selective Cox-2 Inhibitors Product Offered
Table 178. Hengrui pharmaceutical Main Business
Table 179. Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 180. Hengrui pharmaceutical Latest Developments
Table 181. Kelun Group Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 182. Kelun Group Selective Cox-2 Inhibitors Product Offered
Table 183. Kelun Group Main Business
Table 184. Kelun Group Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 185. Kelun Group Latest Developments
Table 186. Qilu Pharmaceutical Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 187. Qilu Pharmaceutical Selective Cox-2 Inhibitors Product Offered
Table 188. Qilu Pharmaceutical Main Business
Table 189. Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 190. Qilu Pharmaceutical Latest Developments
Table 191. Taro Pharmaceuticals Details, Company Type, Selective Cox-2 Inhibitors Area Served and Its Competitors
Table 192. Taro Pharmaceuticals Selective Cox-2 Inhibitors Product Offered
Table 193. Taro Pharmaceuticals Main Business
Table 194. Taro Pharmaceuticals Selective Cox-2 Inhibitors Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 195. Taro Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Selective Cox-2 Inhibitors Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Selective Cox-2 Inhibitors Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Selective Cox-2 Inhibitors Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Selective Cox-2 Inhibitors Sales Market Share by Country/Region (2022)
Figure 8. Selective Cox-2 Inhibitors Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Selective Cox-2 Inhibitors Market Size Market Share by Type in 2022
Figure 10. Selective Cox-2 Inhibitors in Rheumatoid Arthritis
Figure 11. Global Selective Cox-2 Inhibitors Market: Rheumatoid Arthritis (2018-2023) & ($ Millions)
Figure 12. Selective Cox-2 Inhibitors in Osteoarthritis
Figure 13. Global Selective Cox-2 Inhibitors Market: Osteoarthritis (2018-2023) & ($ Millions)
Figure 14. Selective Cox-2 Inhibitors in Spondylosis Chronica Ankylopoietica
Figure 15. Global Selective Cox-2 Inhibitors Market: Spondylosis Chronica Ankylopoietica (2018-2023) & ($ Millions)
Figure 16. Selective Cox-2 Inhibitors in Other
Figure 17. Global Selective Cox-2 Inhibitors Market: Other (2018-2023) & ($ Millions)
Figure 18. Global Selective Cox-2 Inhibitors Market Size Market Share by Application in 2022
Figure 19. Global Selective Cox-2 Inhibitors Revenue Market Share by Player in 2022
Figure 20. Global Selective Cox-2 Inhibitors Market Size Market Share by Regions (2018-2023)
Figure 21. Americas Selective Cox-2 Inhibitors Market Size 2018-2023 ($ Millions)
Figure 22. APAC Selective Cox-2 Inhibitors Market Size 2018-2023 ($ Millions)
Figure 23. Europe Selective Cox-2 Inhibitors Market Size 2018-2023 ($ Millions)
Figure 24. Middle East & Africa Selective Cox-2 Inhibitors Market Size 2018-2023 ($ Millions)
Figure 25. Americas Selective Cox-2 Inhibitors Value Market Share by Country in 2022
Figure 26. United States Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 27. Canada Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 28. Mexico Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 29. Brazil Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 30. APAC Selective Cox-2 Inhibitors Market Size Market Share by Region in 2022
Figure 31. APAC Selective Cox-2 Inhibitors Market Size Market Share by Type in 2022
Figure 32. APAC Selective Cox-2 Inhibitors Market Size Market Share by Application in 2022
Figure 33. China Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 34. Japan Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 35. Korea Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 36. Southeast Asia Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 37. India Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 38. Australia Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 39. Europe Selective Cox-2 Inhibitors Market Size Market Share by Country in 2022
Figure 40. Europe Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
Figure 41. Europe Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
Figure 42. Germany Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 43. France Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 44. UK Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 45. Italy Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 46. Russia Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 47. Middle East & Africa Selective Cox-2 Inhibitors Market Size Market Share by Region (2018-2023)
Figure 48. Middle East & Africa Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
Figure 49. Middle East & Africa Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
Figure 50. Egypt Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 51. South Africa Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 52. Israel Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 53. Turkey Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 54. GCC Country Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 55. Americas Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 56. APAC Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 57. Europe Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 58. Middle East & Africa Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 59. United States Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 60. Canada Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 61. Mexico Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 62. Brazil Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 63. China Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 64. Japan Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 65. Korea Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 66. Southeast Asia Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 67. India Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 68. Australia Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 69. Germany Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 70. France Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 71. UK Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 72. Italy Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 73. Russia Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 74. Spain Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 75. Egypt Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 76. South Africa Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 77. Israel Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 78. Turkey Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 79. GCC Countries Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 80. Global Selective Cox-2 Inhibitors Market Size Market Share Forecast by Type (2024-2029)
Figure 81. Global Selective Cox-2 Inhibitors Market Size Market Share Forecast by Application (2024-2029)
Figure 1. Selective Cox-2 Inhibitors Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Selective Cox-2 Inhibitors Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Selective Cox-2 Inhibitors Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Selective Cox-2 Inhibitors Sales Market Share by Country/Region (2022)
Figure 8. Selective Cox-2 Inhibitors Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Selective Cox-2 Inhibitors Market Size Market Share by Type in 2022
Figure 10. Selective Cox-2 Inhibitors in Rheumatoid Arthritis
Figure 11. Global Selective Cox-2 Inhibitors Market: Rheumatoid Arthritis (2018-2023) & ($ Millions)
Figure 12. Selective Cox-2 Inhibitors in Osteoarthritis
Figure 13. Global Selective Cox-2 Inhibitors Market: Osteoarthritis (2018-2023) & ($ Millions)
Figure 14. Selective Cox-2 Inhibitors in Spondylosis Chronica Ankylopoietica
Figure 15. Global Selective Cox-2 Inhibitors Market: Spondylosis Chronica Ankylopoietica (2018-2023) & ($ Millions)
Figure 16. Selective Cox-2 Inhibitors in Other
Figure 17. Global Selective Cox-2 Inhibitors Market: Other (2018-2023) & ($ Millions)
Figure 18. Global Selective Cox-2 Inhibitors Market Size Market Share by Application in 2022
Figure 19. Global Selective Cox-2 Inhibitors Revenue Market Share by Player in 2022
Figure 20. Global Selective Cox-2 Inhibitors Market Size Market Share by Regions (2018-2023)
Figure 21. Americas Selective Cox-2 Inhibitors Market Size 2018-2023 ($ Millions)
Figure 22. APAC Selective Cox-2 Inhibitors Market Size 2018-2023 ($ Millions)
Figure 23. Europe Selective Cox-2 Inhibitors Market Size 2018-2023 ($ Millions)
Figure 24. Middle East & Africa Selective Cox-2 Inhibitors Market Size 2018-2023 ($ Millions)
Figure 25. Americas Selective Cox-2 Inhibitors Value Market Share by Country in 2022
Figure 26. United States Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 27. Canada Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 28. Mexico Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 29. Brazil Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 30. APAC Selective Cox-2 Inhibitors Market Size Market Share by Region in 2022
Figure 31. APAC Selective Cox-2 Inhibitors Market Size Market Share by Type in 2022
Figure 32. APAC Selective Cox-2 Inhibitors Market Size Market Share by Application in 2022
Figure 33. China Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 34. Japan Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 35. Korea Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 36. Southeast Asia Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 37. India Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 38. Australia Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 39. Europe Selective Cox-2 Inhibitors Market Size Market Share by Country in 2022
Figure 40. Europe Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
Figure 41. Europe Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
Figure 42. Germany Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 43. France Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 44. UK Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 45. Italy Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 46. Russia Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 47. Middle East & Africa Selective Cox-2 Inhibitors Market Size Market Share by Region (2018-2023)
Figure 48. Middle East & Africa Selective Cox-2 Inhibitors Market Size Market Share by Type (2018-2023)
Figure 49. Middle East & Africa Selective Cox-2 Inhibitors Market Size Market Share by Application (2018-2023)
Figure 50. Egypt Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 51. South Africa Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 52. Israel Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 53. Turkey Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 54. GCC Country Selective Cox-2 Inhibitors Market Size Growth 2018-2023 ($ Millions)
Figure 55. Americas Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 56. APAC Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 57. Europe Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 58. Middle East & Africa Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 59. United States Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 60. Canada Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 61. Mexico Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 62. Brazil Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 63. China Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 64. Japan Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 65. Korea Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 66. Southeast Asia Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 67. India Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 68. Australia Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 69. Germany Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 70. France Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 71. UK Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 72. Italy Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 73. Russia Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 74. Spain Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 75. Egypt Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 76. South Africa Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 77. Israel Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 78. Turkey Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 79. GCC Countries Selective Cox-2 Inhibitors Market Size 2024-2029 ($ Millions)
Figure 80. Global Selective Cox-2 Inhibitors Market Size Market Share Forecast by Type (2024-2029)
Figure 81. Global Selective Cox-2 Inhibitors Market Size Market Share Forecast by Application (2024-2029)
